# US 2014/0271814 A1 · Cell binding peptide drug delivery system and compound for treating cancer and tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271814 A1
- Document ID: US20140271814A1
- Status: Published application
- Kind: A1
- Application number: 13/826,120
- Filed: 2013-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Inventors: Shiva Andrali
- Web page: https://patentgrep.com/patent/US20140271814A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is a method and compound for treating cancer and tumors. The invention treats cancer by encapsulating certain cancer fighting drugs in a liposome. Peptides attached to the compound then guide the compound towards its target. During its journey, DSPE-PEG is used to stabilize the compound, to allow more time in the blood stream before losing effectiveness.

## Claims

### Claim 1

A cancer treatment compound comprising:
one or more therapeutic agents in an amount of from 9.0 to 50.0 percent by weight based on a total weight of said cancer fighting compound;
a liposome component in an amount of from 38.0 to 70.0 percent by weight based on a total weight of said cancer fighting compound.

### Claim 2 (depends on 1)

The cancer treatment compound of claim 1, wherein said one or more therapeutic agents are encapsulated in said liposome.

### Claim 3 (depends on 2)

The cancer treatment compound of claim 2, wherein said liposome component comprises a phospholipid bilayer;

### Claim 4 (depends on 3)

The cancer treatment compound of claim 3, further comprising a DSPE-PEG component in an amount from 12.0 to 21.0 percent by weight based on a total weight of said cancer fighting compound; and
wherein said one or more therapeutic agents is doxorubicin.

### Claim 5 (depends on 3)

The cancer treatment compound of claim 3, further comprising:
a peptides component in an amount of from 8.0 to 16.0 percent by weight based on a total weight of said cancer fighting compound; and
a DSPE-PEG component in an amount of from 10.0 to 20.0 percent by weight based on a total weight of said cancer fighting compound;

### Claim 6 (depends on 5)

The cancer treatment compound of claim 5, wherein said peptide component is attached to said liposome component.

### Claim 7 (depends on 6)

The cancer treatment compound of claim 6, wherein said DSPE-PEG component is attached to said peptide component.

### Claim 8 (depends on 7)

The cancer treatment compound of claim 7, wherein said peptides component causes said cancer treatment compound to preferentially bind to tumors, and thereby accumulate at tumors;
wherein said cancer treatment compound releases said one or more therapeutic agents upon binding with tumors.

### Claim 9 (depends on 8)

The cancer treatment compound of claim 8, wherein said DSPE-PEG component stabilizes said cancer treatment compound to allow said cancer treatment compound to spend more time in a bloodstream before becoming less effective.

### Claim 10 (depends on 9)

The cancer treatment compound of claim 9, wherein said one or more therapeutic agents is selected from one or more of the following classes: anti-neoplastic therapeutic agents, non-steroidal anti-inflammatory therapeutic agents, steroidal anti-inflammatory therapeutic agents, nucleic acid or nucleotide sequence for non-viral gene therapy, hormones, peptides, growth factors, antiangiogenic compounds, antisense oligonucleotides, anti-micro RNA molecules, microRNA molecules, herbal drugs, and antibodies.

### Claim 11 (depends on 10)

The cancer treatment compound of claim 10, wherein said one or more therapeutic agents is a cancer fighting drug selected from one or more of the following: gemcitabine, cisplatin, and doxorubicin.

### Claim 12 (depends on 10, 11)

The cancer treatment compound of claim 10 or 11, wherein said peptide component is a Collagen binding peptide.

### Claim 13

A cancer treatment compound comprising:
one or more therapeutic agents in an amount of from 8.0 to 48.0 percent by weight based on a total weight of said cancer fighting compound;
a liposome component in an amount of from 34.0 to 63.0 percent by weight based on a total weight of said cancer fighting compound;
a peptides component in an amount of from 8.0 to 16.0 percent by weight based on a total weight of said cancer fighting compound;
a DSPE-PEG component in an amount of from 12.0 to 21.0 percent by weight based on a total weight of said cancer fighting compound;
wherein said one or more therapeutic agents is selected from one or more of the following classes: anti-neoplastic therapeutic agents, non-steroidal anti-inflammatory therapeutic agents, steroidal anti-inflammatory therapeutic agents, nucleic acid or nucleotide sequence for non-viral gene therapy, hormones, peptides, growth factors, antiangiogenic compounds, antisense oligonucleotides, anti-micro RNA molecules, microRNA molecules, herbal drugs, and antibodies;
wherein said peptides component is a Collagen binding peptide;
wherein said one or more cancer fighting drugs is encapsulated in said liposome component;
wherein said liposome component comprises a phospholipid bilayer;
wherein said peptides component attach to said liposome component, and causes said cancer treatment compound to preferentially bind to tumors;
wherein said cancer treatment compound releases said one or more cancer fighting drugs upon binding with cancerous cells and tumors;
wherein said DSPE-PEG component is attached to said peptide component, and stabilizes said cancer treatment compound to allow said cancer treatment compound to spend more time in a bloodstream before becoming less effective.

### Claim 14 (depends on 13)

The cancer treatment compound of claim 13, wherein said one or more therapeutic agents is selected from one or more of: gemcitabine, cisplatin, and doxorubicin.

### Claim 15 (depends on 14)

The cancer treatment compound of claim 14, wherein said Collagen binding peptide is selected from the group of the peptide sequences consisting of:
Seq1:
Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Leu-Ser
(WREPSFMALS);
Seq2:
Trp-Arg-Glu-Pro-Ser-Phe-Cys-Ala-Leu-Ser
(WREPSFCALS);
Seq3:
Trp-Arg-Asp-Pro-Ser-Phe-Met-Ala-Leu-Ser
(WRDPSFMALS);
Seq4:
Trp-Arg-Asp-Pro-Ser-Phe-Cys-Ala-Leu-Ser
(WRDPSFCALS);
Seq5:
Trp-Arg-Glu-Pro-Ser-Phe-Met-Ala-Ile-Ser
(WREPSFMAIS);
Seq6:
Trp-Arg-Glu-Pro-Ser-Phe-Cys-Ala-Leu-Ser
(WREPSFCALS);
Seq7:
Trp-Arg-Asp-Pro-Ser-Phe-Met-Ala-Leu-Ser
(WRDPSFMALS);
and
Seq8:
Trp-Arg-Glu-Pro-Ser-Phe-Cys-Ala-Leu-Ser
(WREPSFCALS).

### Claim 16 (depends on 15)

The cancer treatment compound of claim 15, wherein said Collagen binding peptides may have a fluorescent dye attached at either end of the peptide by addition of an amino acid sequence PPGP to the front of said Collagen binding peptide.

### Claim 17 (depends on 16)

The cancer treatment compound of claim 16 wherein said Collagen binding peptides have PPGP added to the back end, allowing for tandem repeats of the peptide.
